Date published: 2025-10-25

1-800-457-3801

SCBT Portrait Logo
Seach Input

Olfr1012 Inhibitors

Olfr1012 is an olfactory receptor, part of the large family of G protein-coupled receptors (GPCRs). Direct chemical inhibitors specifically targeting Olfr1012 are not extensively documented. However, considering its classification as a GPCR, we can explore chemicals known to modulate GPCR activity. GPCRs are a large family of cell surface receptors that play key roles in various physiological processes. They are activated by a range of ligands, including hormones, neurotransmitters, and sensory stimuli like odorants. GPCR inhibitors, therefore, encompass a diverse array of chemicals that can modulate the signaling pathways of these receptors. The inhibitors listed above are primarily antagonists for different GPCRs and are chosen based on their potential to influence the activity of Olfr1012 indirectly. These inhibitors work by binding to specific GPCRs or their associated proteins, preventing the normal ligand-receptor interaction or the subsequent intracellular signaling. For example, beta-adrenergic receptor antagonists like Propranolol and Metoprolol bind to beta-adrenergic receptors, inhibiting the normal sympathetic nervous system responses. Similarly, antagonists like Atropine, targeting muscarinic acetylcholine receptors, prevent parasympathetic nervous system actions.

The mechanism of action for these inhibitors varies. Some, like Losartan, block the receptor's active site, preventing ligand binding. Others, like Ondansetron, may cause a conformational change in the receptor, inhibiting its ability to interact with G proteins and initiate signaling cascades. The effects of these inhibitors can alter the overall GPCR landscape, potentially impacting related receptors like Olfr1012. Given the vast and interconnected nature of GPCR signaling, the exact impact of these inhibitors on Olfr1012 is complex and can depend on the specific physiological context. Research into GPCR interactions and signaling pathways continues to evolve, providing deeper insights into how these inhibitors can be used to modulate receptor activity, including in olfactory receptors.

SEE ALSO...

Product NameCAS #Catalog #QUANTITYPriceCitationsRATING

Propranolol

525-66-6sc-507425
100 mg
$180.00
(0)

A non-selective beta-adrenergic receptor antagonist, potentially altering GPCR-mediated signaling.

Carvedilol

72956-09-3sc-200157
sc-200157A
sc-200157B
sc-200157C
sc-200157D
100 mg
1 g
10 g
25 g
100 g
$122.00
$235.00
$520.00
$979.00
$1500.00
2
(1)

A non-selective beta-adrenergic blocker with alpha-1 blocking activity, affecting GPCR signaling.

Yohimbine hydrochloride

65-19-0sc-204412
sc-204412A
sc-204412B
1 g
5 g
25 g
$50.00
$168.00
$520.00
2
(1)

An alpha-2 adrenergic receptor antagonist, potentially modulating GPCR activity.

Losartan

114798-26-4sc-353662
100 mg
$127.00
18
(1)

An angiotensin II receptor antagonist, affecting GPCR-mediated pathways.

Ondansetron

99614-02-5sc-201127
sc-201127A
10 mg
50 mg
$80.00
$326.00
1
(0)

A 5-HT3 receptor antagonist, influencing serotonin GPCRs.

Atropine

51-55-8sc-252392
5 g
$200.00
2
(1)

A muscarinic acetylcholine receptor antagonist, impacting GPCR pathways.

SCH 23390

125941-87-9sc-200408
sc-200408A
5 mg
25 mg
$175.00
$719.00
2
(1)

A dopamine D1 receptor antagonist, modulating GPCR activity.

Nadolol

42200-33-9sc-253175
1 g
$180.00
(1)

A non-selective beta-adrenergic blocker, potentially influencing GPCR-mediated pathways.